Critical Comparison: Bullfrog AI (NASDAQ:BFRG) vs. InflaRx (NASDAQ:IFRX)

InflaRx (NASDAQ:IFRXGet Free Report) and Bullfrog AI (NASDAQ:BFRGGet Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and price targets for InflaRx and Bullfrog AI, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InflaRx 0 0 1 0 3.00
Bullfrog AI 0 0 0 0 0.00

InflaRx presently has a consensus price target of $8.00, indicating a potential upside of 231.95%. Given InflaRx’s stronger consensus rating and higher possible upside, research analysts plainly believe InflaRx is more favorable than Bullfrog AI.

Valuation & Earnings

This table compares InflaRx and Bullfrog AI”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
InflaRx $168,498.00 842.19 -$46.18 million ($1.08) -2.23
Bullfrog AI $60,000.00 320.93 -$5.36 million ($0.85) -2.60

Bullfrog AI has lower revenue, but higher earnings than InflaRx. Bullfrog AI is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares InflaRx and Bullfrog AI’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
InflaRx -33,362.70% -65.98% -56.86%
Bullfrog AI N/A -141.39% -124.63%

Volatility & Risk

InflaRx has a beta of 1.67, meaning that its stock price is 67% more volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500.

Institutional & Insider Ownership

42.4% of InflaRx shares are owned by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are owned by institutional investors. 16.3% of InflaRx shares are owned by insiders. Comparatively, 33.9% of Bullfrog AI shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

InflaRx beats Bullfrog AI on 10 of the 14 factors compared between the two stocks.

About InflaRx

(Get Free Report)

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

About Bullfrog AI

(Get Free Report)

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.